C-MIC: Redefining Heart Failure Therapy

With the C-MIC Device - a Revolutionary, Novel and Life-Saving Treatment for Heart Failure Patients - Berlin Heals has developed an innovative, disruptive and easily implantable low-invasive microcurrent device that has demonstrated tremendous clinical effects never seen before in heart failure patients.

The C-MIC Device

A Revolutionary Life-Saving Treatment for Heart Failure Patients

The C-MIC device is a novel cardiac implant that has evolved in a breakthrough near-curative treatment for patients with systematic and refractory heart failure. The C-MIC is a small implantable device that propagates reverse remodeling of the cardiac muscle tissue by delivering a constant but minimal electrical direct current (DC) to the heart.

Impressive pilot study results

Rapid improvements in heart function, heart size and quality of life of C-MIC placement patients within days of C-MIC placement.
Patients’ average 6-minute walking distance improved by almost 100% after 4 weeks.
Hearts, which were typically enlarged in dilated cardiomyopathies, shrunk in size.
All patients saw their NYHA classification drop by two classes. The NYHA classification is a scheme originally published by the New York Heart Association to classify heart disease according to severity.
The electrical microcurrent remained completely undetectable to the patients and did not interfere with the heart rhythm.
No device-specific side medication or follow-up procedures were required.
Berlin Heals is currently undertaking a European-wide CE Study and is in parallel preparing an Early Feasibility Study in the US.
The patients maintained and increased these improvements for 6 months after implantation.

Heart Failure Explained

Heart Failure is the World’s Most Lethal Disease

Heart Failure is a progressive illness and occurs when the heart muscle is unable to pump enough blood through the heart to meet the body’s needs for blood and oxygen. As no viable therapy, drug or method has ever been developed and made available to reverse heart failure, Berlin Heals was formed in 2014 to address this situation based on an innovative and revolutionary method.

More about Heart Failure

Studies

Study Plan

A First-In-Human study was completed in 2019 with long-term follow-up completed going out to 30months after implant. Then an International Multi-Center Randomized Controlled Trial was completed 2022-2024 and published in 2025. These patients are now being followed for a total duration of 30 months after implant. Then a Less Invasive First-In-Man study was completed in 2025 with results expected in Spring of 2026.

Recent studies

Berlin Heals was established to define a new era of heart failure treatment More about us